Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

被引：22

作者：

Cortellini, Alessio ^{[1
,2
]}

Cannita, Katia ^{[3
]}

Tiseo, Marcello ^{[4
,5
]}

Cortinovis, Diego L. ^{[6
]}

Aerts, Joachim G. J., V ^{[7
]}

Baldessari, Cinzia ^{[8
]}

Giusti, Raffaele ^{[9
]}

Ferrara, Miriam G. ^{[10
,11
]}

D'Argento, Ettore ^{[10
]}

Grossi, Francesco ^{[12
]}

Guida, Annalisa ^{[13
]}

Berardi, Rossana ^{[14
]}

Morabito, Alessandro ^{[15
]}

Genova, Carlo ^{[16
]}

Antonuzzo, Lorenzo ^{[17
]}

Mazzoni, Francesca ^{[17
]}

De Toma, Alessandro ^{[18
]}

Signorelli, Diego ^{[18
,19
]}

Gelibter, Alain ^{[20
]}

Targato, Giada ^{[21
]}

Rastelli, Francesca ^{[22
]}

Chiari, Rita ^{[23
]}

Rocco, Danilo ^{[24
]}

Gori, Stefania ^{[25
]}

De Tursi, Michele ^{[26
]}

Mansueto, Giovanni ^{[27
]}

Zoratto, Federica ^{[28
]}

Filetti, Marco ^{[9
]}

Bracarda, Sergio ^{[29
]}

Citarella, Fabrizio ^{[30
]}

Russano, Marco ^{[30
]}

Cantini, Luca ^{[7
,14
]}

Nigro, Olga ^{[31
]}

Buti, Sebastiano ^{[5
]}

Minuti, Gabriele ^{[32
]}

Landi, Lorenza ^{[32
]}

Ricciardi, Serena ^{[33
]}

Migliorino, Maria R. ^{[33
]}

Natalizio, Salvatore ^{[34
]}

Simona, Carnio ^{[35
]}

De Filippis, Marco ^{[35
]}

Metro, Giulio ^{[36
]}

Adamo, Vincenzo ^{[37
]}

Russo, Alessandro ^{[37
]}

Spinelli, Gian P. ^{[38
]}

Di Maio, Massimo ^{[39
,40
]}

Banna, Giuseppe L. ^{[41
]}

Friedlaender, Alex ^{[42
]}

Addeo, Alfredo ^{[42
]}

Pinato, David J. ^{[2
,43
]}

机构：

[1] Univ LAquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[2] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Div Canc, London, England

[3] St Salvatore Hosp, Med Oncol, Laquila, Italy

[4] Univ Parma, Dept Med & Surg, Parma, Italy

[5] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[6] Osped San Gerardo, Med Oncol, Monza, Italy

[7] Erasmus MC, Dept Pulm Dis, Rotterdam, Netherlands

[8] AOU Policlin Modena, Dipartimeto Oncol Ematol, Modena, Italy

[9] St Andrea Hosp, Med Oncolgy, Rome, Italy

[10] Fdn Policlin Univ Gemelli, Comprehens Canc Ctr, IRCCS, Rome, Italy

[11] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Romae, Lazio, Italy

[12] Fdn IRCCS CaGranda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy

[13] Azienda Osped Santa Maria, Dept Oncol, Terni, Italy

[14] Univ Politecn Marche, Osped Riuniti Ancona, Oncol Clin, Ancona, Italy

[15] Ist Nazl Tumori, IRCCS, Thorac Med Oncol, Fdn G Pascale, Naples, Italy

[16] Osped Policlin San Martino, Lung Canc Unit, IRCCS, Genoa, Italy

[17] Careggi Univ Hosp, Dept Oncol, Florence, Italy

[18] Ist Nazl Tumori, Dept Med Oncol, Fdn IRCCS, Milan, Italy

[19] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy

[20] Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy

[21] Univ Hosp Santa Maria Misericordia, Dept Oncol, Udine, Italy

[22] Med Oncol, Fermo Area Vasta 4, Fermo, Italy

[23] Osped Riuniti Padova Sud Madre Teresa Calcutta, Med Oncol, Monselice, Italy

[24] Monaldi Hosp, Pneumo Oncol Unit, Naples, Italy

[25] Osped Sacro Cuore Don Calabria, IRCCS, Oncol Unit, Negrar, VR, Italy

[26] Oral & Biotechnol Sci Univ G DAnnunzio, Dept Med, Chieti, Italy

[27] Spaziani Hosp, Med Oncol, Frosinone, Italy

[28] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[29] Azienda Osped Santa Maria Terni, Struttura Complessa Oncol Med & Traslaz, Terni, Italy

[30] Campus Biomed Univ, Med Oncol, Rome, Italy

[31] ASST Sette Laghi, Med Oncol, Varese, Italy

[32] AUSL Romagna, Dept Oncol & Hematol, Ravenna, Italy

[33] St Camillo Forlanini Hosp, Pneumo Oncol Unit, Rome, Italy

[34] Univ Modena & Raggio Emilia, Dipartimento Oncol Ematol, Modena, Italy

[35] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, TO, Italy

[36] Azienda Osped Perugia, Dept Med Oncol, Santa Maria Misericordia Hosp, Perugia, Italy

[37] Univ Messina, AO Papardo & Dept Human Pathol, Med Oncol, Messina, Italy

[38] Univ Rome Sapienza, UOC Terr Oncol Aprilia, AUSL Latina, Aprilia, Italy

[39] Univ Turin, Dept Oncol, Turin, Italy

[40] AO Ordine Mauriziano, Med Oncol, Turin, Italy

[41] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[42] Univ Hosp Geneva, Oncol Dept, Geneva, Switzerland

[43] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 148卷

关键词：

Non-small cell lung cancer; Immunotherapy; PD-L1; Pembrolizumab; Performance status; Post-progression; Radiotherapy; Radiation therapy; CELL LUNG-CANCER; IMMUNE-CHECKPOINT INHIBITORS; SALVAGE CHEMOTHERAPY; RESPONSE RATES; IMMUNOTHERAPY; RADIOTHERAPY; ASSOCIATION; ASSAYS;

D O I：

10.1016/j.ejca.2021.02.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Treatment sequencing with first-line immunotherapy, followed by second-line chemotherapy, is still a viable option for NSCLC patients with PD-L1 expression >50%. Methods: We evaluated post-progression treatment pathways in a large real-world cohort of metastatic NSCLC patients with PD-L1 expression > 50% treated with first-line pembrolizumab monotherapy. Results: Overall, 974 patients were included. With a median follow-up of 22.7 months (95%CI: 21.6-38.2), the median overall survival (OS) of the entire population was 15.8 months (95% CI: 13.5-17.5; 548 events). At the data cutoff, among the 678 patients who experienced disease progression, 379 (55.9%) had not received any further treatment, and 359 patients (52.9%) had died. Patients who did not receive post-progression therapies were older (p = 0.0011), with a worse ECOG-PS (p < 0.0001) and were on corticosteroids prior to pembrolizumab (p = 0.0024). At disease progression, 198 patients (29.2%) received a switched approach and 101 (14.9%) received pembrolizumab ByPD either alone (64 [9.4%]) or in combination with local ablative treatments (37 [5.5%]) (LATs). After a random-case control matching according to ECOG-PS, CNS metastases, bone metastases, and (previous) best response to pembrolizumab, patients receiving pembrolizumab ByPD plus LATs were confirmed to have a significantly longer post-progression OS compared to patients receiving pembrolizumab ByPD alone 13.9 months versus 7.8 months (p = 0.0179) 241 patients (35.5%) among the 678 who had experienced PD, received a second-line systemic treatment (regardless of previous treatment beyond PD). As compared to first-line treatment commencement, patients' features at the moment of second-line initiation showed a significantly higher proportion of patients aged under 70 years (p = 0.0244), with a poorer ECOG-PS (p < 0.0001) and having CNS (p = 0.0001), bone (p = 0.0266) and liver metastases (p = 0.0148). Conclusions: In the real-world scenario NSCLC patients with PD-L1 expression >50% treated with first-line single-agent pembrolizumab achieve worse outcomes as compared to the Keynote-024 trial. Poor post-progression outcomes are major determinants of the global results that should be considered when counselling patients for first-line treatment choices. (c) 2021 Elsevier Ltd. All rights reserved.

引用

页码：24 / 35

页数：12

共 50 条

[21] Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with ≥50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
Perea, J.
Gomez, E.
Escriva, C.
Pellicer, A. V.
Rodriguez, P. Llor
Iranzo, J.
Vidal, O. J. Juan
Sanchez, J. Garcia
Montagud, G. Suay
Mico, A. Ferrero
Diaz, J. Linares
Sepulveda, N. Gomez
Hernandez, E. Soria
Gallego, J. Esteve
Carrasco, C.
Gaudens, P. Capdevila
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S72 - S73
[22] A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study)
Watanabe, K.
Hosomi, Y.
Naoki, K.
Kato, T.
Tsukita, Y.
Matsumoto, H.
Yoh, K.
Fujisaka, Y.
Takahashi, S.
Takata, S.
Usui, K.
Kishi, K.
Naka, G.
Tamano, S.
Uemura, K.
Kunitoh, H.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S341 - S342
[23] Pembrolizumab as palliative First-Line Therapy in NSCLC with a PD-L1 Expression of at least 50%: Results from clinical Routine
Frost, N.
Kollmeier, J.
Pultermann, D.
Tessmer, A.
Schmittel, A.
Schmidt, B.
Grah, C.
de Wit, M.
Misch, D.
Blum, T. G.
Suttorp, N.
Witzenrath, M.
Grohe, C.
PNEUMOLOGIE, 2020, 74 : S38 - S38
[24] Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)
Masini, S.
Garrido, A.
Alvarez, R.
Antonanzas, M.
Navarro, F.
Traseira, C.
Cabezon, L.
Garcia, C.
Falagan, S.
Rocha, P.
Mosquera, J.
Azkarate, A.
Garcia-Lorenzo, E.
Martin-Soberon, M. C.
Sequero, S.
Sereno, M.
Lage, Y.
Peressini, M.
Cortijo, S.
Bote, H.
Torres-Jimenez, J.
Zurera, M.
Paz-Ares, L.
Zugazagoitia, J.
Baena, J.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S405 - S405
[25] Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1-positive (TPS ≥50%), advanced NSCLC in Japan
Goto, Y.
Santorelli, M. L.
Taniguchi, K.
Kamitani, T.
Irisawa, M.
Kanda, K.
Abe, M.
Burke, T.
Nokihara, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1008 - S1009
[26] First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment
Velcheti, Vamsidhar
Chandwani, Sheenu
Chen, Xin
Pietanza, M. Catherine
Burke, Thomas
IMMUNOTHERAPY, 2019, 11 (10) : 889 - 901
[27] Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
Frost, N.
Kollmeier, J.
Pultermann, D.
Tessmer, A.
Schmittel, A.
Schmidt, B.
Grah, C.
de Wit, M.
Misch, D.
Blum, T.
Suttorp, N.
Grohe, C.
ANNALS OF ONCOLOGY, 2019, 30
[28] Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line
Zhao, Yue
Mao, Yousheng
He, Jie
Gao, Shugeng
Zhang, Zhirong
Ding, Ningning
Xue, Qi
Gao, Yushun
Wang, Dali
Zhao, Jun
Tan, Fengwei
Yuan, Ligong
Li, Feng
Wang, Shuaibo
Yang, Lin
CLINICAL LUNG CANCER, 2021, 22 (02) : E201 - E210
[29] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
Velcheti, Vamsidhar
Chandwani, Sheenu
Chen, Xin
Pietanza, M. Catherine
Burke, Thomas
CANCER RESEARCH, 2019, 79 (13)
[30] Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Russano, M.
Cantini, L.
B, A. P.
George, R.
Nunes, P.
Tolba, K.
Dutra, C.
Chico, I.
Cortellini, A.
Pecci, F.
Alessi, J. V.
Ricciuti, B.
Ramkissoon, S.
Aerts, J. G.
Agrawal, S.
Saini, K. S.
ANNALS OF ONCOLOGY, 2024, 35 : S854 - S854

← 1 2 3 4 5 →

Post-progression outcomes of NSCLC patients with PD-L1 expression &gt; 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Post-progression outcomes of NSCLC patients with PD-L1 expression > 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study